Harrow Health-Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates

Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of$ 0.25. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 48%. A quarter ago, it was expected that this pharmaceutical and drug compounding company would post a loss of$ 0.25 per share when it actually produced a loss of $0.28, delivering a surprise of -12%. Over the last four quarters, ...